查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612995

临床化学和免疫诊断市场：按产品类型、最终用户划分 - 全球预测 2025-2030

Clinical Chemistry & Immunodiagnostic Market by Product Type (Instruments, Reagents), End-user (Diagnostic Laboratories, Hospitals) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年临床化学和免疫诊断市值为376.7亿美元，预计到2024年将达到400.1亿美元，复合年增长率为6.41%，到2030年将达到582亿美元。

临床化学和免疫诊断市场包括专注于分析体液以进行诊断和健康监测的医疗测试程序。由于慢性病的流行、人口老化和个人化医疗的出现，这一领域变得至关重要。应用范围涵盖疾病诊断、药物开发和病患监测，为包括医院、诊断实验室、研究机构和就地检验设施在内的各种最终用户提供服务。生物标誌物发现、实验室自动化以及人工智慧在诊断中的整合的进步正在推动成长。一个显着的商机在于开发经济高效且快速的 POC 测试解决方案，以提高偏远和资源匮乏环境中的可近性。使用基因组学、蛋白质组学和代谢体学的个人化诊断也提供了精确的医疗保健解决方案并扩大了市场视野。阻碍市场扩张的挑战包括监管障碍、高昂的研发成本和复杂的医疗设备报销。资料隐私问题以及对熟练专业人员管理先进诊断技术的需求进一步增加了复杂性。儘管存在这些挑战，用于资料分析的机器学习演算法的创新、诊断设备的小型化以及测试灵敏度和特异性的改进提供了重要的成长途径。这个市场的动态本质很大程度上是由快速的技术进步和监管适应决定的，需要业务策略制定的灵活性。促进与学术机构的研究合作和参与官民合作关係关係可以促进成长，同时投资强有力的培训计画以缩小技能差距。随着市场竞争的激烈，企业应专注于透过併购巩固自身地位，扩大产品系列，并利用客户回馈进行创新。不断开拓开拓的市场并调整解决方案以服务世界各地不同的经济领域对于在不断变化的市场格局中保持成长和获得竞争优势至关重要。

主要市场统计
基准年[2023] 376.7亿美元
预测年份 [2024] 400.1亿美元
预测年份 [2030] 582亿美元
复合年增长率（%） 6.41%

市场动态：快速发展的临床化学和免疫诊断市场的关键市场洞察

供需的动态交互作用正在改变临床化学和免疫诊断市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 老年人口增加和慢性病盛行率
    • 政府积极采用临床化学和免疫诊断技术
    • 就地检验的重要性和意识不断增强
  • 市场限制因素
    • 化学和免疫诊断产品的回想问题
  • 市场机会
    • 临床化学和免疫诊断设备的持续技术进步
    • 临床化学和免疫诊断在远端医疗和个人化治疗的潜力不断增加
  • 市场挑战
    • 产品开发和商业化监管标准的严格性和多样性

波特五力：驾驭临床化学和免疫诊断市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解临床化学和免疫诊断市场的外部影响

外部宏观环境因素在塑造临床化学和免疫诊断市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析了解临床化学和免疫诊断市场的竞争格局

临床化学和免疫诊断市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵临床化学和免疫诊断市场供应商的绩效评估

FPNV定位矩阵是评估临床化学和免疫诊断市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製临床化学和免疫诊断市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，临床化学和免疫诊断市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年人口增加和慢性病增加
      • 政府对引进临床化学和免疫诊断技术的积极努力
      • 就地检验的重要性和意识不断增强
    • 抑制因素
      • 与化学和免疫诊断产品召回相关的问题
    • 机会
      • 临床化学和免疫诊断设备的持续技术进步
      • 扩大临床化学和免疫诊断在远端医疗和个人化治疗的潜力
    • 任务
      • 产品开发和商业化严格且多样化的监管标准
  • 市场区隔分析
    • 产品类型：采用模组化、可扩展的系统，可轻鬆与现有医院资讯系统集成
    • 最终用户：更加关注设备中的先进技术集成
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章临床化学和免疫诊断市场：按产品类型

  • 装置
  • 试剂

第七章临床化学和免疫诊断市场：按最终用户

  • 诊断实验室
  • 医院

第八章美洲临床化学和免疫诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太临床化学和免疫诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲的临床化学和免疫诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Beckman Coulter DxC 500 AU 化学分析仪简介
    • FUJIREBIO Holdings 与 Agappe Diagnostics 结成战略联盟，彻底改变印度的化学冷光免疫检测生产
    • 罗氏透过收购 LumiraDx 护理点技术扩大诊断产品组合
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Accurex Biomedical Private Limited
  • Agappe Diagnostics Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cardinal Health, Inc.
  • Chengdu Seamaty Technology Co., Ltd.
  • Danaher Corporation
  • DiaSorin SpA
  • ELITechGroup by Bruker Corporation
  • F. Hoffmann-La Roche Ltd.
  • GenviewDX
  • HU Group Holdings Inc.
  • Hitachi, Ltd.
  • HORIBA, Ltd.
  • Immuno Diagnostics Pvt. Ltd.
  • Medix Biochemica AB
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Sekisui Medical Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens AG
  • Thermo Fisher Scientific Inc.
  • viSole The Solution
Product Code: MRR-CB04E0565D32

The Clinical Chemistry & Immunodiagnostic Market was valued at USD 37.67 billion in 2023, expected to reach USD 40.01 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 58.20 billion by 2030.

The Clinical Chemistry & Immunodiagnostic market involves medical testing procedures that focus on analyzing bodily fluids for diagnostic and health monitoring purposes. This sector is integral due to chronic disease prevalence, aging populations, and the advent of personalized medicine. Applications span disease diagnosis, drug development, and patient monitoring, serving diverse end-users such as hospitals, diagnostic labs, research institutions, and point-of-care testing facilities. Growth is fueled by advancements in biomarker discovery, automation in laboratories, and the integration of artificial intelligence in diagnostics. A notable opportunity lies in developing cost-effective, rapid point-of-care testing solutions to enhance accessibility in remote or resource-poor settings. Personalized diagnostics, which leverage genomics, proteomics, and metabolomics, are also expanding the market's horizon, offering precise healthcare solutions. Challenges hindering market expansion include regulatory obstacles, high RD costs, and complexities in medical device reimbursement. Data privacy concerns and the need for skilled professionals to manage sophisticated diagnostic technologies add further layers of complexity. Despite these challenges, innovation in machine learning algorithms for data analysis, miniaturization of diagnostic devices, and enhancing the sensitivity and specificity of tests present significant growth avenues. The dynamic nature of this market is largely shaped by rapid technological progress and regulatory adaptations, demanding agility in strategy formulation for companies. Fostering collaborations with academic institutions for research and engaging in public-private partnerships could catalyze growth, alongside investing in robust training programs to bridge skill gaps. As the market is highly competitive, businesses should focus on consolidating their positions through mergers and acquisitions, expanding their product portfolios, and leveraging customer feedback to innovate. Continuous exploration of untapped markets and the adaptation of solutions to cater to varied economic segments worldwide will be crucial in sustaining growth and gaining a competitive edge in this evolving market landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 37.67 billion
Estimated Year [2024] USD 40.01 billion
Forecast Year [2030] USD 58.20 billion
CAGR (%) 6.41%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Clinical Chemistry & Immunodiagnostic Market

The Clinical Chemistry & Immunodiagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising elderly population and growing prevalence of chronic diseases
    • Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
    • Growing importance and awareness of point-of-care testing
  • Market Restraints
    • Issues associated with chemistry and immunodiagnostic product recall
  • Market Opportunities
    • Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
    • Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
  • Market Challenges
    • Stringent and varying regulatory standards for product development and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Clinical Chemistry & Immunodiagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Clinical Chemistry & Immunodiagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Clinical Chemistry & Immunodiagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Clinical Chemistry & Immunodiagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Clinical Chemistry & Immunodiagnostic Market

A detailed market share analysis in the Clinical Chemistry & Immunodiagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Clinical Chemistry & Immunodiagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Clinical Chemistry & Immunodiagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Clinical Chemistry & Immunodiagnostic Market

A strategic analysis of the Clinical Chemistry & Immunodiagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Clinical Chemistry & Immunodiagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accurex Biomedical Private Limited, Agappe Diagnostics Ltd., Bio-Rad Laboratories, Inc., bioMerieux SA, Cardinal Health, Inc., Chengdu Seamaty Technology Co., Ltd., Danaher Corporation, DiaSorin S.p.A, ELITechGroup by Bruker Corporation, F. Hoffmann-La Roche Ltd., GenviewDX, H.U. Group Holdings Inc., Hitachi, Ltd., HORIBA, Ltd., Immuno Diagnostics Pvt. Ltd., Medix Biochemica AB, QIAGEN N.V., Quest Diagnostics Incorporated, QuidelOrtho Corporation, Sekisui Medical Co. Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens AG, Thermo Fisher Scientific Inc., and viSole The Solution.

Market Segmentation & Coverage

This research report categorizes the Clinical Chemistry & Immunodiagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Instruments and Reagents.
  • Based on End-user, market is studied across Diagnostic Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising elderly population and growing prevalence of chronic diseases
      • 5.1.1.2. Favorable government initiatives for adoption of clinical chemistry & immunodiagnostic techniques
      • 5.1.1.3. Growing importance and awareness of point-of-care testing
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with chemistry and immunodiagnostic product recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing technological advancements in clinical chemistry and immunodiagnostic instruments
      • 5.1.3.2. Growing potential of clinical chemistry & immunodiagnostic in telemedicine and personalized therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and varying regulatory standards for product development and commercialization
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Adoption of modular and scalable systems that easily integrate with existing hospital information systems
    • 5.2.2. End-user: Growing focus on advanced technological integration in instruments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Clinical Chemistry & Immunodiagnostic Market, by Product Type

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents

7. Clinical Chemistry & Immunodiagnostic Market, by End-user

  • 7.1. Introduction
  • 7.2. Diagnostic Laboratories
  • 7.3. Hospitals

8. Americas Clinical Chemistry & Immunodiagnostic Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Clinical Chemistry & Immunodiagnostic Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Clinical Chemistry & Immunodiagnostic Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Introduction of Beckman Coulter's DxC 500 AU Chemistry Analyzer
    • 11.3.2. Strategic Partnership Between Fujirebio Holdings and Agappe Diagnostics to Revolutionize Chemiluminescence Immunoassay Production in India
    • 11.3.3. Roche Expands Diagnostics Portfolio with Acquisition of LumiraDx Point of Care Technology
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Accurex Biomedical Private Limited
  • 3. Agappe Diagnostics Ltd.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Cardinal Health, Inc.
  • 7. Chengdu Seamaty Technology Co., Ltd.
  • 8. Danaher Corporation
  • 9. DiaSorin S.p.A
  • 10. ELITechGroup by Bruker Corporation
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. GenviewDX
  • 13. H.U. Group Holdings Inc.
  • 14. Hitachi, Ltd.
  • 15. HORIBA, Ltd.
  • 16. Immuno Diagnostics Pvt. Ltd.
  • 17. Medix Biochemica AB
  • 18. QIAGEN N.V.
  • 19. Quest Diagnostics Incorporated
  • 20. QuidelOrtho Corporation
  • 21. Sekisui Medical Co. Ltd.
  • 22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 23. Siemens AG
  • 24. Thermo Fisher Scientific Inc.
  • 25. viSole The Solution

LIST OF FIGURES

  • FIGURE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET RESEARCH PROCESS
  • FIGURE 2. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET DYNAMICS
  • TABLE 7. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. CLINICAL CHEMISTRY & IMMUNODIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023